Pfizer - RULE OUT AL Amyloidosis Due to its Clinical Urgency

Please use landscape view or desktop screen to view the content.

RULE OUT AL Amyloidosis Due to its Clinical Urgency^1,2

Monoclonal plasma cells overproduce immunoglobulin light chain fragments, which misfold to form amyloid fibrils¹

BONE MARROW

PLASMA CELL

IMMUNOGLOBULIN

LIGHT-CHAINS

MISFOLDING

AMYLOID FIBRILS

~3000 new cases per year in the United States¹
AL typically presents in patients aged >50 years²
It can be distinguished from other types of amyloidosis through various testing methods^1,3
Median survival of untreated patients with AL with cardiac involvement is <6 months¹
It is important to rule out AL as it is considered a hematologic emergency, and the treatment regimen is very different from that for transthyretin amyloidosis (ATTR)¹

	n	All the 5 tests	Serum PEL and IFE; urine IFE	Serum PEL, IFE, and FCL	Serum PEL and FLC	Serum IFE	Serum PEL	Serum FLC

Diagnosis, n
All	1877	1851	1821	1828	1770	1632	1482	1395
MM	467	467	461	467	467	441	409	452
Macroglobulinemia	26	26	26	26	26	26	26	19
SMM	191	191	191	191	190	188	180	155
MGUS	524	524	524	509	465	468	429	222
Plasmacytoma	29	26	26	26	25	21	21	16
POEMS	31	30	30	30	23	30	23	3
Extramedullary plasmacytoma	10	2	2	1	1	1	1	1
Primary AL	581	570	547	564	559	429	382	513
LCDD	18	15	14	14	14	10	10	14
Diagnosis, %
All		98.6	97.0	97.4	94.3	87.0	79.0	74.3
MM		100.0	98.7	100.0	100.0	94.4	87.6	96.8
Macroglobulinemia		100.0	100.0	100.0	100.0	100.0	100.0	73.1
SMM		100.0	100.0	100.0	99.5	98.4	94.2	81.2
MGUS		100.0	100.0	97.1	88.7	92.8	81.9	42.2
Plasmacytoma		89.7	89.7	89.7	88.2	72.4	72.4	55.2
POEMS		96.8	96.8	96.8	74.2	96.8	74.2	9.7
Extramedullary plasmacytoma		70.0	20.0	10.0	10.0	10.0	10.0	10.0
Primary AL		98.1	94.2	97.1	96.2	73.8	65.9	88.3
LCDD		83.3	77.8	77.8	77.8	55.6	55.6	77.8